Vyne Therapeutics Inc (VYNE) Smart Money Holdings (13F, Q2 2026)

Yarrow Bioscience, Inc. (ticker: VYNE) reported that on July 29, 2026 it entered into an exchange agreement with an existing stockholder, swapping 133,290 shares of common stock for pre-funded warrants to buy the same number of shares at $0.0001 per share. The warrants are immediately exercisable, expire when exercised in full, and include a 9.99% beneficial ownership limitation that the holder can raise to up to 19.99% with 61 days' notice. The exchange closed the same day; after it, the company has 2,669,788 common shares outstanding plus pre-funded warrants to purchase 25,914,530 common shares.

Yarrow Bioscience (ticker VYNE) entered into new indemnification agreements with its directors and executive officers on July 27, 2026, replacing the prior ones. The 8-K filing reports this contractual change but does not disclose any financial terms or amounts.

No AI summary for this filing type

AI summary pending

VYNE Therapeutics Inc. made an investor presentation from Yarrow Bioscience, Inc. available on its website on July 14, 2026. The presentation, attached as Exhibit 99.1, is intended for investor relations purposes. This filing also references VYNE's proposed transaction with Yarrow and directs investors to the related S-4 registration statement for more details.

No AI summary for this filing type